BRPI0919248A2 - derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol - Google Patents

derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol

Info

Publication number
BRPI0919248A2
BRPI0919248A2 BRPI0919248A BRPI0919248A BRPI0919248A2 BR PI0919248 A2 BRPI0919248 A2 BR PI0919248A2 BR PI0919248 A BRPI0919248 A BR PI0919248A BR PI0919248 A BRPI0919248 A BR PI0919248A BR PI0919248 A2 BRPI0919248 A2 BR PI0919248A2
Authority
BR
Brazil
Prior art keywords
aminoindazole
amino
tetrahydroindazole derivatives
tetrahydroindazole
derivatives
Prior art date
Application number
BRPI0919248A
Other languages
English (en)
Inventor
Kuhn Bernd
Martin Benson Gregory
Richter Hans
Plancher Jean-Marc
Bleicher Konrad
Rudolph Markus
E Martin Rainer
Feng Song
Taylor Sven
Grether Uwe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0919248A2 publication Critical patent/BRPI0919248A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0919248A 2008-09-25 2009-09-15 derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol BRPI0919248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08165137 2008-09-25
PCT/EP2009/061966 WO2010034657A1 (en) 2008-09-25 2009-09-15 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives

Publications (1)

Publication Number Publication Date
BRPI0919248A2 true BRPI0919248A2 (pt) 2019-09-24

Family

ID=41382044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919248A BRPI0919248A2 (pt) 2008-09-25 2009-09-15 derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol

Country Status (14)

Country Link
US (1) US8153663B2 (pt)
EP (1) EP2346834B1 (pt)
JP (1) JP5450632B2 (pt)
KR (1) KR101444988B1 (pt)
CN (1) CN102164900B (pt)
AR (1) AR073396A1 (pt)
AU (1) AU2009295967A1 (pt)
BR (1) BRPI0919248A2 (pt)
CA (1) CA2736434A1 (pt)
ES (1) ES2443947T3 (pt)
IL (1) IL211674A0 (pt)
MX (1) MX2011002793A (pt)
TW (1) TW201020234A (pt)
WO (1) WO2010034657A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735886A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag Indazole or 4,5,6,7-tetrahydro-indazole derivatives
US8252826B2 (en) * 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
EP2593078B1 (en) * 2010-05-25 2016-11-30 Symrise AG Cyclohexyl carbamate compounds as active anti-cellulite ingredients
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ, インコーポレイテッド Fxrアゴニストの固体形態
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN113372276B (zh) * 2021-05-25 2022-04-22 三峡大学 吲唑类衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1974379A (en) * 1932-10-12 1934-09-18 Cinch Mfg Corp Coupling device for hose and like connections
US1966325A (en) * 1933-06-28 1934-07-10 Verne E Welch Pump
GB865341A (en) * 1958-07-30 1961-04-12 Bayer Ag 5-benzene-sulphonamido-1-phenyl pyrazole derivatives
GB926327A (en) 1960-05-13 1963-05-15 Ici Ltd New dyestuffs of the azostilbene series containing halopyrimidyl residues
GB1145544A (en) 1966-07-16 1969-03-19 Polichimica Sap S P A New tetrahydroindazoles
NL6707299A (pt) * 1966-07-16 1968-01-17
PL360243A1 (en) 2000-06-23 2004-09-06 Takeda Chemical Industries,Ltd Benzoxazepinones and their use as squalene synthase inhibitors
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CN100448869C (zh) * 2002-11-27 2009-01-07 拜尔药品公司 用于治疗糖尿病的苯胺基吡唑衍生物
AR042067A1 (es) 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および/または治療剤
CA2628260A1 (en) 2005-11-09 2007-05-18 Abbott Laboratories 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer

Also Published As

Publication number Publication date
CA2736434A1 (en) 2010-04-01
KR20110059890A (ko) 2011-06-07
JP5450632B2 (ja) 2014-03-26
ES2443947T3 (es) 2014-02-21
EP2346834A1 (en) 2011-07-27
US8153663B2 (en) 2012-04-10
AR073396A1 (es) 2010-11-03
TW201020234A (en) 2010-06-01
EP2346834B1 (en) 2013-11-20
CN102164900A (zh) 2011-08-24
CN102164900B (zh) 2014-04-16
WO2010034657A1 (en) 2010-04-01
KR101444988B1 (ko) 2014-09-26
IL211674A0 (en) 2011-06-30
US20100076026A1 (en) 2010-03-25
MX2011002793A (es) 2011-04-05
JP2012503618A (ja) 2012-02-09
AU2009295967A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0919248A2 (pt) derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0923730A2 (pt) "elemento deslizante".
BRPI0918472A2 (pt) composto 2,4-diaminopirimidina
BRPI0906607A2 (pt) Agentes de coalescência eficazes.
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE540040T1 (de) Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0813235A2 (pt) Combinação anti-helmíntica.
BRPI0814745A2 (pt) Composição de produto.
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0923048A2 (pt) "composto de aminopirazol".
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
FR2928371B1 (fr) Derive de cysteine.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.